KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Debt Repayments (2020 - 2023)

Royalty Pharma (RPRX) has disclosed Long-Term Debt Repayments for 2 consecutive years, with -$650.0 million as the latest value for Q4 2023.

  • Quarterly Long-Term Debt Repayments changed N/A to -$650.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$650.0 million through Dec 2023, changed N/A year-over-year, with the annual reading at $350.0 million for FY2023, N/A changed from the prior year.
  • Long-Term Debt Repayments hit -$650.0 million in Q4 2023 for Royalty Pharma, down from $5.9 billion in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $5.9 billion in Q3 2020 to a low of -$650.0 million in Q4 2023.